# Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

> **NCT05046613** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 780 (estimated)

## Conditions studied

- Migraine

## Interventions

- **OTHER:** Rimegepant
- **OTHER:** Not taking Rimegepant

## Key facts

- **NCT ID:** NCT05046613
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-23
- **Primary completion:** 2029-11-04
- **Final completion:** 2034-04-30
- **Target enrollment:** 780 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046613, "Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05046613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*